|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FAM210A |
Gene summary for FAM210A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FAM210A | Gene ID | 125228 |
| Gene name | family with sequence similarity 210 member A | |
| Gene Alias | C18orf19 | |
| Cytomap | 18p11.21 | |
| Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | Q96ND0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 125228 | FAM210A | LZE2T | Human | Esophagus | ESCC | 7.32e-04 | 5.82e-01 | 0.082 |
| 125228 | FAM210A | LZE4T | Human | Esophagus | ESCC | 8.01e-10 | 3.52e-01 | 0.0811 |
| 125228 | FAM210A | LZE7T | Human | Esophagus | ESCC | 2.82e-04 | 1.18e-01 | 0.0667 |
| 125228 | FAM210A | LZE20T | Human | Esophagus | ESCC | 3.25e-04 | 1.73e-02 | 0.0662 |
| 125228 | FAM210A | LZE24T | Human | Esophagus | ESCC | 5.83e-05 | 1.59e-01 | 0.0596 |
| 125228 | FAM210A | LZE6T | Human | Esophagus | ESCC | 2.61e-03 | 4.23e-02 | 0.0845 |
| 125228 | FAM210A | P2T-E | Human | Esophagus | ESCC | 6.78e-20 | 3.42e-01 | 0.1177 |
| 125228 | FAM210A | P4T-E | Human | Esophagus | ESCC | 6.96e-22 | 5.06e-01 | 0.1323 |
| 125228 | FAM210A | P5T-E | Human | Esophagus | ESCC | 2.52e-62 | 9.75e-01 | 0.1327 |
| 125228 | FAM210A | P8T-E | Human | Esophagus | ESCC | 1.58e-15 | 1.56e-01 | 0.0889 |
| 125228 | FAM210A | P9T-E | Human | Esophagus | ESCC | 1.99e-13 | 4.23e-01 | 0.1131 |
| 125228 | FAM210A | P10T-E | Human | Esophagus | ESCC | 2.03e-14 | 2.18e-01 | 0.116 |
| 125228 | FAM210A | P11T-E | Human | Esophagus | ESCC | 3.23e-13 | 9.94e-01 | 0.1426 |
| 125228 | FAM210A | P12T-E | Human | Esophagus | ESCC | 4.52e-21 | 4.13e-01 | 0.1122 |
| 125228 | FAM210A | P15T-E | Human | Esophagus | ESCC | 1.64e-10 | 4.74e-01 | 0.1149 |
| 125228 | FAM210A | P16T-E | Human | Esophagus | ESCC | 7.54e-16 | 3.45e-01 | 0.1153 |
| 125228 | FAM210A | P19T-E | Human | Esophagus | ESCC | 1.62e-02 | 2.32e-01 | 0.1662 |
| 125228 | FAM210A | P20T-E | Human | Esophagus | ESCC | 2.44e-19 | 3.90e-01 | 0.1124 |
| 125228 | FAM210A | P21T-E | Human | Esophagus | ESCC | 7.40e-33 | 5.49e-01 | 0.1617 |
| 125228 | FAM210A | P22T-E | Human | Esophagus | ESCC | 1.16e-19 | 2.44e-01 | 0.1236 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FAM210A | SNV | Missense_Mutation | c.245N>C | p.Arg82Pro | p.R82P | Q96ND0 | protein_coding | tolerated(0.37) | benign(0) | TCGA-AR-A1AH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | PD | ||
| FAM210A | SNV | Missense_Mutation | rs762433160 | c.487G>A | p.Val163Ile | p.V163I | Q96ND0 | protein_coding | tolerated(0.43) | benign(0.047) | TCGA-B6-A0I1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| FAM210A | deletion | Frame_Shift_Del | novel | c.390delN | p.Phe130LeufsTer8 | p.F130Lfs*8 | Q96ND0 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| FAM210A | SNV | Missense_Mutation | c.733N>A | p.Glu245Lys | p.E245K | Q96ND0 | protein_coding | deleterious(0.02) | possibly_damaging(0.588) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| FAM210A | SNV | Missense_Mutation | rs779671314 | c.13N>A | p.Val5Ile | p.V5I | Q96ND0 | protein_coding | tolerated_low_confidence(0.32) | benign(0.001) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD |
| FAM210A | SNV | Missense_Mutation | c.374G>A | p.Arg125Gln | p.R125Q | Q96ND0 | protein_coding | deleterious(0) | benign(0.341) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| FAM210A | SNV | Missense_Mutation | c.679N>T | p.Pro227Ser | p.P227S | Q96ND0 | protein_coding | deleterious(0.03) | possibly_damaging(0.563) | TCGA-EI-6882-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| FAM210A | deletion | Frame_Shift_Del | c.271delN | p.Ser91HisfsTer47 | p.S91Hfs*47 | Q96ND0 | protein_coding | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |||
| FAM210A | SNV | Missense_Mutation | rs764696749 | c.650N>A | p.Arg217His | p.R217H | Q96ND0 | protein_coding | deleterious(0.02) | possibly_damaging(0.828) | TCGA-AJ-A23O-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FAM210A | SNV | Missense_Mutation | c.374N>A | p.Arg125Gln | p.R125Q | Q96ND0 | protein_coding | deleterious(0) | benign(0.341) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |